DYADIC INTERNATIONAL INC 10-Q

Item 5. Other Information (a) None. (b) None. (c) During the quarter ended June 30, 2024, the following individuals adopted Rule 10b5 - 1 trading arrangements, which are intended to satisfy the affirmative defense of Rule 10b5 - 1 (c) under the Exchange Act: our President and Chief Executive Officer Mark Emalfarb ( adopted on June 4, 2024 ); our director Jack Kaye ( adopted on June 6, 2024 ); our Vice President of Research and Business Development Ronen Tchelet ( adopted on June 7, 2024 ); and our Chief Financial Officer Ping Wang Rawson ( adopted on June 12, 2024 ). Each trading arrangement includes the potential sale of up to a specified number of shares of our common stock owned by the applicable individual (for Mr. Emalfarb, 1 million; for Mr. Kaye, 292,367; for Mr. Tchelet, 250,000; and for Ms. Rawson, 282,485 ), and expires on a specified date (for Mr. Emalfarb, December 31, 2026; for Mr. Kaye, June 2, 2026; for Mr. Tchelet, June 10, 2025; and for Ms. Rawson, June 12, 2026), unless earlier terminated in accordance with the provisions of the arrangement. Except as described above, for the quarter ended June 30, 2024, none of our directors or officers (as defined in Section 16 of the Exchange Act) adopted or terminated a “Rule 10b5 - 1 trading arrangement” or a “non-Rule 10b5 - 1 trading arrangement” (each as defined in Item 408 (a) and (c), respectively, of Regulation S-K). Item 6. Exhibits The following Exhibits are filed as part of this report pursuant to Item 601 of Regulation S-K: Incorporated by Reference Exhibit No. Description of Exhibit Form Original No. Date Filed Filed Herewith 3.1 Restated Certificate of Incorporation dated November 1, 2004 10-12G 3.1 January 14, 2019 3.2 Third Amended and Restated Bylaws dated March 28, 2023 8-K 3.1 March 29, 2023 10.1 License and Development Agreement between Dyadic International (USA), Inc. and Proliant Biologicals, LLC d/b/a Proliant Health and Biologicals, dated June 27, 2024 (1) 8-K 10.1 July 2, 2024 31.1 Certification of Principal Executive Officer of Dyadic Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 x 31.2 Certification of Principal Financial Officer of Dyadic Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 x 32.1 Certification of Principal Executive Officer of Dyadic Pursuant to18 U.S.C Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (2) 32.2 Certification of Principal Financial Officer of Dyadic Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (2) 101.INS Inline XBRL Instance Document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Labels Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101) (1) Portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K. (2) Furnished herewith. 23 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DYADIC INTERNATIONAL, INC. August 13, 2024 By: /s/ Mark A. Emalfarb Mark A. Emalfarb President and Chief Executive Officer (Principal Executive Officer) August 13, 2024 By: /s/ Ping W. Rawson Ping W. Rawson Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) 24